Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

June 17th 2024

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL

June 15th 2024

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

FDA Approves Blinatumomab for CD19+ B-ALL in the Consolidation Phase

June 14th 2024

The FDA has approved blinatumomab (Blincyto) for use in select patients with CD19+ Ph– B-cell precursor acute lymphoblastic leukemia in the consolidation phase.

Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL

June 14th 2024

Blinatumomab consolidation improved MRD clearance over chemotherapy in DS B-ALL patients, according to ALLTogether1 DS study results.

FDA Grants Accelerated Approval to Repotrectinib for NTRK+ Solid Tumors

June 13th 2024

The FDA granted accelerated approval to repotrectinib (Augtyro) for select patients with solid tumors harboring a NTRK gene fusion.

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

June 10th 2024

The European Commission has approved alectinib for adjuvant use in adult patients with ALK+ non–small cell lung cancer at high risk of recurrence.

FDA Approves Imetelstat for Low- to Intermediate-1–Risk MDS With Transfusion-Dependent Anemia

June 7th 2024

The FDA has approved imetelstat (Rytelo) for select patients with myelodysplastic syndrome and transfusion-dependent anemia.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

June 4th 2024

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma

Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/Chemo as a SOC for Resectable NSCLC

June 3rd 2024

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer

June 2nd 2024

Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

June 2nd 2024

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.

Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 2nd 2024

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

June 1st 2024

The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive patients with myelofibrosis.

Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations

June 1st 2024

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

May 29th 2024

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer

May 29th 2024

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer

May 29th 2024

CT041 was safe and showcased early signals of antitumor activity in heavily pretreated patients with metastatic pancreatic cancer.

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in High-Risk Early TNBC

May 28th 2024

Perioperative pembrolizumab plus chemotherapy improved survival vs preoperative chemotherapy in high-risk, early-stage, triple-negative breast cancer.

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.